Quick Search  in all journalsin this journalin this issue Journals Home Drugs of Today Issues Drugs of Today Policies & Guidelines Permissions My Profile Contact Us Shopping Cart Purchase History

	Drugs of Today		Register or sign in
	Drugs Today 2012, 48(10): 645 ISSN 1699-3993 e-ISSN 1699-4019 Copyright 2012 Clarivate CCC: 1699-3993 DOI: 10.1358/dot.2012.48.10.1860771
	Linagliptin as add-on therapy for type 2 diabetes - An overview Brown, D.X., Choudhury, M., Evans, M.
	The pathogenesis of type 2 diabetes (T2D) can result in decreased levels of glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which under normal circumstances increase insulin secretion and suppress glucagon release. A new form of drug therapy known as dipeptidyl peptidase 4 (DPP IV) inhibitors has focused on increasing the circulating levels of these "incretin" hormones in order to improve glycemic control in patients with T2D. The DPP IV inhibitors saxagliptin, vildagliptin, linagliptin, alogliptin and sitagliptin function by inhibiting the enzyme DPP IV, which breaks down GLP-1 and GIP, and have had significant success. However, with most DPP IV inhibitors being extensively excreted renally, this is a significant issue, as a large proportion of diabetic patients suffer from renal complications. Linagliptin is a novel DPP IV inhibitor that is excreted primarily by the hepatic route, with little need for dose adjustment in patients with renal impairment. It therefore represents a major advancement in the pharmacotherapy of patients with T2D. Full Text: PDF

	© Clarivate. All rights reserved.
	Copyright Notice	Terms of Use	Privacy Statement	Cookie Policy	Manage cookie preferences